Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford Health Plan (OXHP) -- Ignore unavailable to you. Want to Upgrade?

To: john douglas who wrote (763)	1/16/1998 4:50:00 PM
From: Premier	Read Replies (2) \| Respond to of 2068

John: Zacks email service was my source. Someone familiar to Cowen may obtain full report. Here is an opinion about the analyst's report on 3/20/97: ***** On March 20, 1997 Cowen & Company analyst Miriam Willard issued a 11 page Company Report on OXFORD HLTH PLN. Report highlights: " A STRONG BUY rating was maintained. The company has proven historically to be one of the best percentage grower of enrollment and earnings. EPS growth for the year should range between 45%-50% due to price increases in NY and CT for HMS/POS product, strong enrollment growth, and recent reserve additions. A 12-month price target of $80 was given " Miriam Willard has not made enough stock forecasts to be meaningfully ranked relative to 27 other analysts following Oxford Health Plans, Inc. Miriam Willard is ranked 11 out of 28 when forecasting EPS for Oxford Health Plans, Inc. ****** As you can see, history has proved her wrong. Premier